(Reuters) – Moderna Inc has completed the real-time review process for its application to the U.S. Food and Drug Administration (FDA) seeking full approval for its COVID-19 vaccine in people aged 18 years and above, the company said on Wednesday.
As part of the completed submission, Moderna has requested a priority review designation for its vaccine.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Saumyadeb Chakrabarty)
